Calidi Biotherapeutics, Inc. CLDI
are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic
medicines to distal sites of disease. Our proprietary RedTail platform features an engineered enveloped oncolytic virus designed for
systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune
clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $45.0K | — | — |
| R&D | $9.7M | $8.9M | $13.0M | $7.3M | — | — |
| SG&A | $10.5M | $12.9M | $16.0M | $15.9M | — | — |
| Total operating expenses | $20.2M | $21.8M | $29.0M | $23.2M | — | — |
| Operating income | -$20.2M | -$21.8M | -$29.0M | -$23.1M | — | — |
| Pre-tax income | -$20.0M | -$22.2M | -$29.2M | -$25.4M | — | — |
| Income tax | $15.0K | $14.0K | $16.0K | $11.0K | — | — |
| Net income | -$19.9M | -$22.1M | -$29.2M | -$25.4M | — | — |
| EPS, basic | -5.95 | -35.70 | -17.33 | 2.99 | — | — |
| EPS, diluted | -5.95 | -35.70 | -17.33 | 2.99 | — | — |
| Shares, diluted (wtd. avg.) | $4.3K | $667 | $1.7M | $8.5M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $5.8M | $9.8M | $2.2M | $590.0K | $2.2M | — |
| Receivables | — | — | — | $870 | $0 | — |
| Total current assets | $6.3M | $10.2M | $4.3M | $786.0K | $1.5M | — |
| Property, plant and equipment | $781.0K | $869.0K | $1.3M | $887.0K | — | — |
| Total assets | $8.9M | $14.2M | $10.0M | $2.6M | $231.8M | — |
| Accounts payable | — | — | — | $51.1K | $63.8K | — |
| Short-term debt | $90.0K | $3.2M | $807.0K | $5.4M | — | — |
| Total current liabilities | $3.9M | $9.5M | $10.2M | $43.0M | $411.0K | — |
| Long-term debt | $600.0K | $600.0K | $2.1M | — | — | — |
| Total liabilities | $5.1M | $12.2M | $18.3M | $43.4M | $16.5M | — |
| Retained earnings | -$141.6M | -$121.7M | -$99.6M | -$70.4M | -$14.7M | — |
| Total equity | $3.8M | $1.5M | -$8.2M | -$50.4M | -$31.6M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$21.3M | -$19.7M | -$27.0M | -$13.2M | — | — |
| Depreciation and amortisation | — | $402.0K | $392.0K | $260.0K | — | — |
| Stock-based compensation | $2.1M | $3.0M | $4.8M | $4.5M | — | — |
| Investing cash flow | -$170.0K | -$16.0K | -$478.0K | -$494.0K | — | — |
| Financing cash flow | $17.5M | $27.4M | $29.0M | $12.1M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013242.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |